Citi raised the firm’s price target on Zymeworks (ZYME) to $35 from $22 and keeps a Buy rating on the shares. The company announced positive HERIZON-GEA-01 study data, showing Ziihera in combination with chemotherapy demonstrated a statistically significant progression-free survival benefit versus trastuzumab plus chemo in first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. Citi upped the probability of success for Ziihera.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Midday Fly By: Berkshire takes Alphabet stake, J&J buying cancer drug maker
- Morning Movers: E.W. Scripps surges after report of Sinclair takeover interest
- Zymeworks Announces Positive Phase 3 Trial Results
- Zymeworks’ Ziihera shows efficacy in Phase 3 adenocarcinoma trial
- Zymeworks’ Earnings Call: Revenue Soars Amid Challenges